title: [Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostate cancer eligible for first line chemotherapy (VIABLE) - AUO study AP 78/13].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence, Seestraße 11, 17252, Schwarz, Deutschland, AUO@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D019496:Cancer Vaccines / Q000008:administration & dosage*; D002277:Carcinoma / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D002369:Castration; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology; D000077143:Docetaxel; D004311:Double-Blind Method; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D006801:Humans; D008297:Male; D015990:Placebo Effect; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*; D012307:Risk Factors; D043823:Taxoids / Q000008:administration & dosage*; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D043823:Taxoids; D000077143:Docetaxel